A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples